Company intelligence / Profile preview

Facotil

Ownership: Private
Development stage: Other

Overview

Facotil is a pharmaceutical brand primarily associated with the production and distribution of gastrointestinal medications, most notably its formulation of famotidine. The company focuses on providing therapeutic solutions for acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers. Facotil operates as a commercial-stage entity, supplying essential small molecule treatments to regional markets. Its product portfolio is centered on histamine H2-receptor antagonists and other digestive health products.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Facotil.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Facotil.

Explore the full profile